Dermatologic Therapy
Download
Report
Transcript Dermatologic Therapy
Using New Technology to Improve
Quality of Care & Profit
John A. McGreal Jr., O.D.
Missouri Eye Associates
McGreal Educational Institute
Excellence in Optometric Education
John A. McGreal Jr., O.D.
Missouri Eye Associates
11710 Old Ballas Rd.
St. Louis, MO. 63141
314.569.2020
314.569.1596 FAX
[email protected]
JAM
Autologous Serum for PED
Tears contain EGF, vitamin A, TGF-B, fibronectin and
other cytokines…..all found in serum
40ml of blood from venipuncture centrifuged for 5 min
–
–
diluted to 20% by physiologic saline (empiric)/UV bottle
Dosed at 6-10 X/D with additional AFTs
Results
–
–
–
43% healed within 2 wks, all within several months
Serum accelerates migration of corneal epithelial cells
Serum upregulates mucin expression of corneal epithelium
Amniotic Membrane
Transplantation (AMT)
Ocular surface reconstruction in SJS, severe dry eye,
and severe chemical burns
Human amniotic membrane prepared from placenta of
elective cesarean section in seronegative (HIV, HepB
&C, syphilis)
Facilitates epithelialization, reduces inflammation,
vascularization and scarring
Limbal stem cell transplantation is needed in concert
with AMT in the most severe chemical burns
RPS Adeno Detector™
Test Procedure
Assembling the Detector
1. Locate the Test Cassette
2. Assemble the detector by gently
placing the sampling pad of the
Sample Collector into the
sample transfer window of the
Test Cassette body.
3. Press firmly where indicated until
the detector is secure.
Transfer Window
Note: A double auditable click means the detector
is properly assembled, transferring the sample to the test strip.
RPS Adeno Detector™
Test Procedure
Running the Test
1. Open the buffer vial. Remove
the Protective Cap from the
Test Cassette. Do not allow
any portion of the detector
besides the absorbent tip to
touch the buffer vial.
2. Immerse the Assembled
Detector’s Absorbent Tip into
the buffer vial for 15 seconds.
RPS Adeno Detector™
Reading & Interpreting the Results
Positive Results:
The Results Line and Control Line are RED in the result window,
indicating that Adenovirus antigen is present.
Results Line
Control Line
Control Line
RPS Adeno Detector™
Reading & Interpreting the Results
Positive Results:
Note:
An uneven or incomplete test
line is due to an uneven
distribution of eye fluid on the
sample pad.
Even if the test line is faint in
color, incomplete over the width
of the test strip, or uneven in
color, it must be interpreted as
positive.
Results Line
RPS Adeno Detector™
Reading & Interpreting the Results
Invalid Results:
If the Control Line does not appear, the test must be interpreted
as invalid and discarded.
Note:
The Patient should be
re-tested with a new
RPS Adeno Detector
kit.
NO Control Line
Antiviral Therapy - Oral
Acyclovir (Zovirax 200/400/800mg)
–
–
–
–
Primary Herpes Simplex: 400mg- 5x/D x10D
Chronic Suppressive: 400mg bid qd
Varicella: 20mg/kg- 4x/D x 5D
Herpes Zoster: 800mg- 5x/D x 10D
Famciclovir (Famvir 500mg tid x 7D)
Valacyclovir (Valtrex 1000mg tid x 7D)
Vaccine for Zoster prevention
–
Zoster Vaccine Live (Zostavax)
Levofloxacin
Fluoroquinolone
Indications
–
Action – DNA gyrase
–
–
–
Conjunctivitis, injuries, pre and post operative care,
pneumonia, sinus, skin and skin structure, GI, GU
Prevents bacterial replication
Broadest spectrum, low toxicity, low resistance
Left stereoisomer of ofloxacin, therefore similar solubility and actions
Side effects – taste perversion
Available as
–
–
Quixin 0.5%/1.5% (topical) – q2h x 4 days, then q4h for
conjunctivitis
Levaquin 500mg, Leva-pak 750mg, 25mg/ml q24h
Ophthalmic Azithromycin: AzaSite
AzaSite™ pairs DuraSite® drug delivery
technology with azithromycin (1.0%)
Azithromycin has not been previously
used in ophthalmology
–
A stable aqueous formulation is difficult
AzaSite™: A stable, easily delivered
formulation of azithromycin
–
All the advantages of topical ophthalmic
delivery
Glaucoma Evolution
POAG
Diagnostics
Therapeutics
Future
Considerations
Glaucoma Evaluation is Transforming
In the past, detection & management relied on
functional assessment
–
Visual fields (white-on-white)
Insensititve
for detecting early POAG
High degree of variability
Recently, structural change over time longitudinal
studies have validated the role of structural
imaging
–
Are structural defects with normal functional tests
false positives or POAG?
JAM
Glaucoma Suspect
CPT / ICD
–
–
–
–
–
CPT / ICD
–
–
–
99214 / Glaucoma Suspect (365.01) = $80.00
92020 / (365.01) = $25.00
76514 / (365.01) = $15.00
92250 / (365.01) = $70.00
92083 / (365.01) = $70.00
99213 or 92012 / (365.01) = $50.00 or $63.00
92235-RT, 92235-LT / (365.01) = $90.00
Total $400.00 or $413.00
Rx: Initiate or continue treatment or observe
Use V58.69 in addition to ICD code when changing medications
in a glaucoma patient
JAM
Gonioscopy
92020
Bilateral
Requires documentation
–
describe visible angle structures
No limitations to diagnostic groups in most states
Fee
$25.71
JAM
Digital Gonioscopy
92020
SL-OCT (Heidelberg)
–
–
–
–
–
–
–
Integrated Slit lamp & digital gonioscopy system
Haag-Streit BD 900 slit lamp, OCT scanning unit
High resolution grey scale or false color reports
Fast, easy, non-contact OCT at any position
Stores data
Measures angle, angle opening distance, angle recess area,
trabecular iris contact length, trabecular iris space area
Measures pachymetry and biometry
JAM
TM
SL-OCT Hardware Features
Non-contact
Fast and easy to use
Simultaneous
optical and OCT exam
Color or gray-scale images
Limitations of Manual
Gonioscopy
Patient discomfort – full globe contact
Time consuming
Subjective
Requires considerable skill and experience
Statement of Assoc. of International Glaucoma Societies (AIGS)
3rd Global Consensus Meeting, May 2006
Pachymetry
76514
Bilateral
Measurement of central corneal thickness (CCT) proven
by Ocular Hypertension Treatment Study (OHTS) to be
standard of care in diagnosis and management of
glaucoma, glaucoma suspect and ocular hypertension
Also billable for keratoconus, corneal transplants,
cataracts with corneal dystrophies, guttata, edema
Requires Interpretation & Report
Fee
$11.92
JAM
CCT Assessment
Has become standard
Equipment widely available
– DGH was used in OHTS
– Low cost
Consider potential effect of
LASIK on IOP findings
Also billable for nonglaucoma ICD-9 codes
–
Corneal edema, keratoconus
Reichert IOPac
Portable, battery op.
Stores up to 1000 pats.
USB and infrared interface
Down load to PC and printer
Detachable
–
probe
Easily replaced if necessary
Download
PDR into Palm
Pachymetry
IOP correction by correlation to corneal thickness is NOT
POSSIBLE!
–
–
A linear relationship does not exist!
Careful examination of regression analysis (scatter graph of IOP
relative to CCT) demonstrates huge bandwidth
Adjusting IOP by CCT instills a degree of accuracy into an
inaccurate measurement
It is possible to adjust the IOP in the WRONG direction
Barbados study of black patients shows no correlation of
CCT/IOP
“Trying to be more precise than this is not supported by the data
and may be harmful to patient care” Jamie Brandt, MD Dir
Glauc Src, UCD / OHTS investigator
JAM
Serial Tonometry
92100
Bilateral
Requires Interpretation & Report
–
–
Example: Angle closure glaucoma
multiple measurements over time
Fee
$55.91-
JAM
PASCAL at work:
Slit lamp mounted
Technique similar to
GAT but…
Constant light pressure
No fluorescein
Self-calibrating
Battery operated
Pascal DCT
Measures
–
–
–
–
–
Ocular Pulse Amplitude
(OPA)
IOP
Quality (Q)
Heart Pulse (H)
Stores data
The PASCAL SensorTip
Contour-matched concave tip
surface (7mm)
–
Accurate for corneal radius 5.59.2mm and CCT 300-700
built-in pressure sensor (1.2mm)
transparent tip permits view of
cornea interface for centering and
control
Comparison of DCT With the GAT
Univ.
Of Zurich
228 eyes measure with DCT and GAT
Compared IOP measurements
Looked at effects of:
–
–
–
–
–
CCT
Corneal curvature
Astigmatism
AC Depth
Axial length
Intra-observer
and Inter-observer variability
DCT vs. GAT
DCT median difference: DCT +1.7mm higher than
GAT
GAT: Affected by CCT, curvature, astigmatism, AC
depth and axial length
DCT: NO EFFECT with any parameters
DCT vs. GAT
Intra-observer variability
–
–
GAT 1.1mm
DCT 0.65mm
Inter-observer variability
–
–
GAT 1.28mm
DCT 0.44mm
Kaufman et. al. IOVS 2004; 45:3118-3121
IOP Measurements Using DCT After
LASIK
“Corneal ablation of 90.0+/-49.18microns reduced
IOP as measured by GAT by 3.0+/-mm. ..no
significant change in IOP was recorded by DCT(0.2MM)”
Kaufmann C, et al IOVS 2003; 44:9:3790-3794
Biomechanical Properties in Tonometry
Flatter corneas = lower IOP
Thinner corneas = Lower IOP
Softer corneas = lower IOP
Stiffer IOP = higher IOP
How accurate is Goldmann in thick, soft cornea?
How accurate is Goldmann in thin, stiff cornea?
Pascal DCT removes biomechanical properties from
measurements
Cannot correct IOP using thickness alone!
–
Linear correction factors of GAT will not accurately correct IOP
DCT in Ectatic Corneas
Study of 53 eyes at Will’s by Ozbek & Cohen
Included eyes with keratoconus, Pellucid Marginal
Degeneration and penetrating keratoplasty
–
–
–
Topography = 54.7 X 43.6
CCT = 482
DCT = 16.1 / GAT = 14.3 / TP = 13.8
DCT were not different between PMD, KC, PK
DCT were not affected by corneal steepening
Conclusions
“IOP measurements by DCT are highly concordant with
IOP readings obtained by GAT but do not vary in CCT
and have a lower intra- and inter-observer variability.
DCT seems to be an appropriate method of tonometry
for routine clinical use”
James Brandt, MD
Director Glaucoma Services
UC Davis
“Assuming that CCT can be used
as a correction factor for GAT is
a misinterpretation of the results
of OHTS… that couldn’t be
further from the truth. Adjusting
IOP based on CCT is attempting
to instill a degree of precision
into a flawed measurement. You
may actually correct in the
wrong direction. The issues
related to the most accurate
tonometry need to include the
material properties of the
cornea”
Ocular Pulse Amplitude (OPA)
Amplitude
and shape of OPA are easily observed with DCT
OPA is a function of
–
–
–
Vascular geometry & flexibility
Ocular rigidity
Systemic blood pressure
Can
be used to assess ocular perfusion
Data now suggests a correlation between OPA & Ocular
rigidity…and hence between OPA & risk of glaucoma
progression
A. Harris, PhD (Indiana University)
Latino Eye Study
How often is GAT significantly low?
Median difference between DCT & GAT studied
>4.5mmHg = 10.6%
– >5.5mmHg = 4.4%
– >6.5mmHg = 2.5%
–
Increased
IOP still most common factor
in optometric practice converting
normals to glaucoma suspects
IOP Measurements By DCT After LASIK
“Corneal ablation of 90.0 +/- 49.18u reduced IOP
as measured by GAT by 3.0mm...no significant
change in IOP was recorded by DCT (-0.2MM)”
Clinically validated by manometric studies of
true intracameral pressure
LASIK case volume in US is 7,401,400
–
GAT DOES NOT WORK!
Kaufmann C, et al IOVS 2003; 44:9:3790-3794
Case of “I Have A Peculiar Nerve”
45yowm CC: “OD wants R/O Papilledema”, Indistinct
optic discs, IOP 20-25 range, pach 637
PH: Hodgkin’s disease, R hip replacement, 3 vessel
CABG, HTN, Hyperlipidemia
FH: + POAG paternal aunt
Meds: Darvocet,Amitryptilline, nitrate, isosorbide,
norvasc,toprol, plavix, lipitor, ASA
VA 20/20 OU PERRL-APD
IOP: 26/23
Pach: 639
SLE: Nl OU
Fundus : As shown
What is the diagnosis?
1.
2.
3.
4.
5.
Normal optic nerves
Papilledema
Optic nerve drusen
Ocular histoplasmosis
Choroidal nevus
What tests are indicated?
1.
2.
3.
4.
5.
VF / Pach / SCODI / Stereo disc photos
MRI
MRI / VF
Histoplasmosis titres
IVFA / VF
Case of “I Have A Peculiar Nerve”
45yowm CC: “OD wants R/O Papilledema”,
DCT
OD: 24.9 / OPA 4.4 / Q3
DCT OS: 23.1 / OPA 3.8 / Q3
SLE: Nl OU Fundus : As prev
VF OD: Superior and inferior nasal defects
VF OS: minor changes
SCODI: Confirms disc elevation limited to disc itself
Visual Field 9208x
Bilateral
Requires Interpretation
–
–
separate report form
narrative in body of medical record, on date of service
Fee $43.88- (-81)
$57.37+ (-82)
$65.92- (-83)
JAM
Oculus Easy Field Perimeter
Screening
AND Threshold
fields
Color LCD-Display
Fixation monitoring
–
CCD camera
Stores
up to 40,000 exams
Built-in printer
FDT Perimetry Abnormalities as
Predictors of Glaucomatous VF Loss
105 eyes of 105 glaucoma suspects
–
–
IOP 23mm+ or disc damage on photos
SAP VF normal
Baseline FDT obtained
Mean follow-up 41 months
Medeiros FA, et al AJO 137:863-871, 2004
FDT as Predictor of VF Loss
16% (17 pats.) converted on SAP VF
In pats. with abnl. FDT at baseline:
–
–
Probability of developing abnl. SAP:
30%
Pats. With NL FDT at baseline:
–
–
Probability of developing abnl. SAP:
4%
FDT as Predictor of VF Loss
Location of the FDT and SAP defects corresponded
in 14 of 17 patients
FDT defects in 59% of the converters occurred as
much as 4 years before SAP
–
Mean: 21 months
However…..
Only 59% of SAP defects were previously
identified by abnl. FDT
24% had SAP defects BEFORE FDT
18% of converters NEVER developed FDT
defect
24% of normal SAP’s showed abnl. FDT but
never developed abnl. SAP
–
False positives?
Other Important VF Studies
Paczka (2001) - found FDT better overall performance
in detecting damage than RNFL photographs
Kondo (1998), Wu (2001) - In patients with SAP VFDs
restricted to 1 hemifield, FDT has shown to be able to
detect functional losses in the other hemifield
Medeiros (2004) – functional defects in FDT predict
future defects on SAP
Other Important VF Studies
Kim (2007/AAO) – when SAP is normal, some patients
with VFD detected by FDT showed decreased NFL
thickness (OCT)
–
Provide evidence that coincident FDT & OCT abnormalities
may be an early sign of glaucoma
Visual Field Testing for Specific
Functions
Short wavelength autoperimetry (SWAP)
–
Frequency doubling technology (FDT)
–
Magnocellular ganglion cells
Motion automated perimetry (MAP)
–
Bistratified ganglion cell (9%) short-wavelength cones
Magnocellular ganglion cells (3%)
High pass resolution perimetry (HPRP)
–
Parvocellular ganglion cells
Visual Field Testing for Specific
Functions
Standard Autoperimetry (SAP)
–
–
–
Achromatic perimetry
Non-specific for ganglion cell type
Appreciable portion of nerve fibers lost before defect measured
Short wavelength autoperimetry (SWAP)
–
–
440nm, 1.6degree tartget @ 200ms yellow background
More sensitive by 3-5 years to early loss
–
UCD studied for over decade
Disadvantages – time consuming, variable, not bright enough to
threshold in advanced POAG
Visual Field Testing for Specific
Functions
Frequency doubling technology (FDT)
–
–
–
–
0.25 cycle/sec sinusoidal grating with 25Hz counterphase
flicker
View grating at low spatial frequency and high temporal rate
Percept is double frequency illusion attributable to subset of
magnocellular ganglion cells
Portable, fast, reproducible
Visual Field Testing for Specific
Functions
Motion automated perimetry (MAP)
–
–
–
–
Tests Magnocellular ganglion cells (3%)
Present random dot kinematogram with coherent motion on
uniform grey background in 14 locations
Computer controlled stimulus (1024x768), 30degree field, 7
frames in rapid succession (420ms), 20 dots/frame, in circular
7.3 degree angle, moving at 8 degree/sec
Superior to SAP in early detection, but time consuming and
high variability
Visual Field Testing for Specific
Functions
High pass resolution perimetry (HPRP)
–
–
–
–
–
Parvocellular ganglion cells system detection
Test presents spatially filtered rings, 50 test locations in
30degree field, 14 different ring sizes used @165 ms
6 minutes, easy
Very useful in following progression
Lacks standardization
A Comparison of Humphrey SITAStandard Perimetry With Both Screening
Oculus Easyfield Perimetry And With
Screening FDT
Seitzman,G.D., Robin,A.L., et al
–
Dept. of Oph., Johns Hopkins University
Objective
To determine the sensitivity and specificity of the
screening modes of the Oculus Easyfield Perimeter and
Frequency Doubling Testing when compared with SITA
standard threshold perimetry.
Methods
One hundred one subjects had the following perimetric
testing: Frequency Doubling Technology (screening
mode), Oculus Easyfield Perimetry (suprathreshold
mode), and Zeiss Humphrey SITA Standard C-24-2
threshold perimetry.
Results
The sensitivity and specificity of detecting any
glaucomatous visual field defect using an abnormal
Glaucoma Hemifield Testing criterion was 76% and
89% for the FDT and 86% and 98% of the Oculus
Perimeter, respectively.
Conclusions
Both smaller screening perimeters were relatively quick.
Although the Oculus was just 30 seconds slower than
the FDT, its increased sensitivity and specificity could
be much more cost effective in the treatment of
glaucoma.
Octopus 301 Perimeter
Motorized
auto eye tracking
100% fixation control
Blazing fast speed
Ergonomic design patient friendly
Blue yellow testing in 3 min/eye
Critical fusion testing
One min screen
Three min full threshold
PeriTrend Analysis
LAN ethernet
800.787.5426
www.haag-streit.com
Closing
Statements
Advances
in perimetry
are continuing
–
Customization for specific needs
–
SWAP allows early recognition, HPRP follows progression
SAP perimetry will continue to be preferred for established
glaucoma with VFDs
–
Early detection / established glaucoma / screening
Early VF loss is often selective, with specific types of axons
disturbed
–
Faster third generation algorithms reduce test time by 50%
Considerably improved methods of computer-assisted interpretations
of serial VFs
Screening methods will sacrifice sensitivity for specificity and
ease of use to detect the half of glaucoma patients who have
undiagnosed disease
–
Deployed in non-professional environments
Closing
Statements
Perimetry is a robust method of examination, a cornerstone of
glaucoma management and will remain so
It will become more user and patient friendly
VF testing is easy to administer (technician)
VF instruments are not expensive
VF testing can still be performed in cataract patients
Computer-assisted analysis (ie Glaucoma Hemifield Test)
performs as well as trained observers and are extremely
specific
–
Asman Arch Ophthalmol 1992
Closing
Statements
Standard SAP testing is not optimal
Combination testing of 2 or more modalities improves
detection
Glaucomatous optic atrophy may precede currently
measurable functional loss in some
Functional loss with specific tests may precede
detection of glaucoma disc changes on stereo
photograph review
Most sensitive test may be different for each stage of
the disease
Fundus Photography
92250
Bilateral
Not Bundled
Stereo disc photography
Requires Interpretation
Fee $73.67+
JAM
Fundus Retinal Photos ROI
Synemed (Canon)
Cost $24,500.00
Lease $543.90
Breakeven 2 photos / wk
6 MP digital non-mydriatic
10 images / wk – lease =
$22,273.20 annual revenue
Extended Ophthalmoscopy
92225 / 92226
Unilateral
Initial (-225) vs. Subsequent (-226)
Implies detailed, extra ophthalmoscopy
–
document fundus lenses used
Modifiers RT /LT
Requires retinal drawings & interpretation
–
sizes, colors and dimensions carrier specific
Fee
92225 ($22.23+)
92226 ($20.01+)
JAM
Scanning Computerized Ophthalmic
Diagnostic Imaging
92135
Unilateral
Applies to glaucoma and retinal evaluations
–
–
–
–
Retinal Thickness Analyzer (RTA)
Heidelberg Retinal Topography (HRT3)
Humphrey Optical Coherence Tomography (OCT)
Laser Diagnostic Technology (GDX VCC)
Requires Interpretation & report
Fee
$45.59
JAM
Scanning Laser
Covered Diagnosis List
362.85 retinal nerve fiber bundle defects 377.00-377.04
364.22 glaucomatocyclitic crisis
Papilledema
364.53 pigmentary iris degeneration
364.73 goniosynechiae
364.74 pupillary membranes
364.77 recession of the angle
365.00-365.9 glaucoma
368.40-368.45 visual field defects
JAM
377.9 unspecified disorder of optic nerve or pathways
Scanning Laser
92135
Moderate Damage - payable once or twice per year, not
with a field
–
Visual field examples
moderate reduction in retinal sensitivity
temporal wedge
–
Optic Nerve examples
enlarged
cup with sloped or pale rim
focal notch
rim/disc >0.1 but <0.2
prominent lamina cribrosa
JAM
Scanning Laser
92135
Advanced Damage - rarely payable, fields more
valuable
–
Visual field examples
loss
of central vision
temporal island remains
severe reduction in retinal sensitivity
absolute defects to within 3 degrees of fixation
–
Optic Nerve examples
rim
destroyed
rim/disc ratio<0.1
JAM
GDx VCC
Image acquisition in less than
1 second
Uses internal fixation device
Compact, table-top design
Portable
Easiest to use
Comfortable, objective test for
patients
Easy interpretation
What’s NEW in the HRT3
OHTS Ancillary Study Results
GPS Glaucoma Probability Score
Enhanced Glaucoma Analysis
Enhanced Progression Software
Portable Design
More operator friendly
Choose from four packages
Top 5 Stereometric Parameters
Rim Area
Rim Volume
Cup Shape Measure
Height Variation Contour
Mean RNFL Thickness
DIAGNOSE: CUP, RIM & RNFL
Optic disc size measure and
“small”, “average” and
“large”
Parameters adjusted for disc
size
Largest normative database
Ethnic-selectable
OU asymmetry
RNFL normative data
Quality Indicator
Conclusion:
Complete Assessment
Monitor Change Over Time
Baseline
–
compared to follow-up images
Absolute change calculated
Progression
Change Probability Analysis
Pixel by pixel comparison
– Independent of reference plane
– No contour line is needed
–
Progression
–
Trend Report
Normalized stereometric parameters graphically displayed
How Predictive is the HRT?
Regression Analysis – measures
rim area & adjusts for disc size
40% of patients flagged at baseline as “outside of
Moorfields
normal limits” by Moorfields Temporal Superior sector
analysis developed glaucoma.
26% of patients flagged at baseline as “outside normal
limits” by Moorfields Global analysis developed
glaucoma
90% of those with normal HRTs did not develop
glaucomatous damage over the next 5 years
Glaucoma Probability Score (GPS)
What if we could take the world’s leading glaucoma
experts and use their combined knowledge to help you
diagnose your patients?
The Glaucoma Probability Score takes the first step in
this direction by applying machine learning to glaucoma
diagnostics.
GPS Advanced Artificial Intelligence
"Find a bug in a program, and fix it, and the program
will work today. Show the program how to find and
fix a bug, and the program will work forever."
- Oliver G. Selfridge, in AI's Greatest Trends and
Controversies
Glaucoma Probability Score
A new approach to optic disc analysis
6 years in development
Applies the latest in artificial intelligence to glaucoma
diagnostics – “Relevance Vector Machine”
Produces an understandable indicator - probability of
disease
Eliminates the need for contour lines or reference planes
GPS How It Works
Uses same HRT scan as in the past
Performs 3-dimensional shape
analysis
Relevance Vector Machine is
“trained” to look for glaucoma
Measures 5 key parameters
3 parameters represent cup shape and
2 represent RNFL
Healthy
Glaucomatous
Case of the “Ocular migraine?”
Age: 43yowm CC: “Flashes of light”
HPI: 20mins / OU / once / 3L soda/Day / -HA, nausea,
vomiting / overweight
Meds: synthroid
Allergy: none
BVA: OU 20/20 Pupils: PERRL-APD
EOM: full
EXT: NL, CA auscultation Nl
Pach: 528/532 SLE: Nl OU IOP 24/24,17/17
VF: normal Optic N: OD 0.80 OS 0.65
OcHx: Mother & brother susp ONH & Nl VFs
Support Literature
Heidelberg Engineering website:
www.heidelbergengineering.com
–
–
–
–
Complete list of published articles on all products
Abstracts of published articles
Condensed summary of the supporting literature for main
topics of interest
Downloadable tutorials for all HE products
Optical Coherence Tomography OCT
Optical: Light-based
Coherence: property of light waves in which the
oscillations maintain a fixed relationship to
each other
Tomography: Cross-sectional imagery
How OCT works
Similar to ultrasound but uses light instead of
sound to image tissue
Beam of light is directed into tissue and
reflections coming from different layers of the
tissue are received by a detector
Stratus OCT Software
Macula
Thickness
Analysis
RNFL Analysis
ONH Analysis
RNFL analysis
Circular scanning around ONH
at a radius of 1. 73mm
Scan begins temporally
Three scans are acquired and
data is averaged
Optic nerve head analysis
Radial scanning across
optic nerve head
Six 4mm scans are taken
Optic Nerve Head Parameters
Volumetric Information
–
Dimensional
Information
–
–
–
Volume of Cup
Disk Area
Cup Area
Rim Area
Cup Disk Ratios
–
–
–
Horizontal
Vertical
Average
Ophthalmic Genetics
Researchers have identified genes for OAG
–
–
TIGR/Myocilin = juvenile OAG
OPTN (optineurin) = Primary OAG (NTG)
–
Optineurin may provide neuroprotection to optic N
CYP1B1 = Congenital glaucoma
Genetic testing will allow clinicians to determine if Pt is
predisposed to or affected with specific type of glaucoma, even
before symptoms appear
OcuGene (InSite Vision/Alimeda) – simple, in office test, 99%
accurate detection of TIGR (trabecular meshwork inducible
glucocorticoid response gene)
–
Positives may be treated more aggressively, earlier
Blood Flow Analysis
Paradigm/Dicon
TonoPlus Tonograph
–
–
–
–
Pulsatile Ocular blood flow analysis
Identifies ocular ischemic syndromes
Reimbursable procedure
Small laptop size
Anti-Glaucoma Agents
Non-Selective B-Adrenergic Antagonists
–
–
–
Timolol (Timoptic 0.25%, 0.50%, XE, Istalol/Ista
Pharmaceuticals)
Levobunolol (Betagan 0.25%, 0.50%)
Metipranolol (Optipranolol 0.3%)
Selective B-Adrenergic Antagonists
–
–
–
Betaxolol (Betoptic-S 0.25%, 0.50%)
Levobetaxolol (Betaxon)
Carteolol (Ocupress 1.0%)
Anti-Glaucoma Therapy
Adrenergic Agonists
–
–
–
–
Dipivefrin (Propine 0.1%)
Epinephrine (Epinal,Eppy-N, Epifrin, Glaucon)
Apraclonidine (Iopidine 0.5%, 1.0%)
Brimonidine (Alphagan 0.2%, Alphagan P-0.1%, 0.15%) /
Timolol (Combigan)
41% less ocular allergy with Alphagan P vs Alphagan over 12 months
Only ophthalmic glaucoma drug without BAK
Cholinergic
–
Pilocarpine (Pilocar 0.50% - 8.0%, Pilogel 4%)
–
Carbachol (Carbachol 0.75%, 1.5%, 2.25%, 3%)
Echothiophate Iodide (0.03%, 0.06%, 0.125%, 0.25%)
–
Antiglaucoma - CAI
Topical
–
–
–
Dorzolamide (Trusopt)
Dorzolamide-Timolol (Cosopt)
Brinzolamide (Azopt)
Oral
–
–
–
Acetazolamide (Diamox)
Methazolamide (Neptazane, MZM)
Dichlorphenamide (Darinide)
Anti-Glaucoma Agents
Prostaglandin Analogue
–
–
–
–
–
Latanoprost (Xalatan 0.005%)
Bimatoprost (Lumigan 0.03%)
Travoprost (Travatan 0.004%/ Extravan with timolol 0.5%)
Travaprost (Travatan Z 0.004%) – No BAK
Unoprostone (Rescula 0.15%)
Pipeline
–
DE-085 (Santen) prostaglandin based; phase II
Low Tension Glaucoma
Compromised ocular blood flow
50% have a cause / find it / fix it
–
–
–
–
Past hx transfusions, bleed, hypovolemic
Medications: B-blockers, digoxin, digitalis
MRI: orbits & brain
R/O all cardiovascular causes of LTG
CBC/anemias, CA doppler, TEE, sleep studies, coagulaopathies (PTT), overly
fit (low BP)
Treatment
–
–
Decrease IOP, avoid B blockers, start with PG, bromonidine, CAIs
last resort
Ginko biloba 60mg/D: inc fluidity without affecting platelet
aggregation
Surgical Glaucoma Therapy
Argon Laser Trabeculoplasty (ALT, LTP)
Selective Laser Trabeculoplasty (SLT)
–
–
–
–
Q switched Nd:YAG selectively targets pigmented
trabecular cells (increasing activity?)
Increases immune system by increasing monocytes &
macrophages in TM
Selective because it does not cause appreciable damage to
TM
50 confluent applications to 180 degrees @0.06mJ
No
–
blanching or bubble phase needed
Addresses greatest roadblock = compliance with medical
therapy
Surgical Glaucoma Therapy
Trabeculectomy
Trabeculectomy with surgical adjuncts
–
–
Indications
–
–
–
–
5 FU (lower risk eyes)
Mitomycin-C (MMC) – higher risk eyes
Maximum tolerated medical therapy
Progression of disease
Unable to instill medications
Secondary glaucomas (Neovascular glaucoma)
Consideration
–
–
–
–
Age, HTN, DM, Anticoagulants, Preop IOP, previous vitrectomy
Degree of visual impairment,
Lens status
Comorbidities
Surgical Glaucoma Therapy
Future directions
–
Newer antifibrinolytics
CAT-12,
–
–
a monoclonal antibody to TGF-B2
Photodynamic therapy
Novel drug delivery systems
Collagen
implants, bioerodable polymers, liposomes &
microspheres
–
Glaucoma drainage implants instead of filtering surgery
Shunts
–
aqueous from AC tube through an episcleral plate
Ocular genetics
Discover
genes, gene therapy, primary prevention of glaucoma
may become a reality
Glaucoma Pipeline
Extracellular Matrix metalloproteinases
Oral neuroprotectants - Memantine (Nameda)
Sustained release formulations
Anecortave acetate (Retaane/Alcon) – ARVO 2006
–
–
–
–
Originally studied for ARMD
Steroid that actually LOWERS IOP
No cataract formation
25% decrease in IOP at six months after 1 juxtascleral
injection
Theories on Aging and Eye Disease
Age related macular degeneration and cataracts are
associated with age
–
–
–
–
–
–
–
Leading causes of blindness worldwide
Elderly
Family history, gender, cardiovascular disease
Smoking – nicotine, benzopyrene, nickel, lead and arsenic
Light colored irides and hair
Exposure to UV radiation
Diet – saturated fat intake increases risk for AMD
Mechanisms – free radical damage, UV damage
AMD Risk Factors
Age > 60
Race W>B
Sex F>M
HTN
Smoking
Nutrition
Family History
Fair complexion
Cardiovascular disease
New Ideas in AMD
Sub-subspecialty emerging in Retina
Devices to measure Macular Pigment Optical Density
–
–
Macuscope
QuantifEye (ZeaVision)
Hyperacuity perimetry
–
Forsee PHP (Notal/MSS)
Zeaxanthin is considered important in supplementation
Combination therapies more common in wet AMD
AMD Research on Genetics
Age related macular degeneration gene located
Encodes for a protein called Compliment Factor H
–
–
Increases inflammatory proteins
Increases C-reactive protein
We now know a genetic component of the disease
exists!
Components of Ocular Supplements
Vitamins
–
–
–
Minerals
–
–
–
Zinc
Copper
Selenium
Macular pigments
–
–
Vitamin A as beta carotene
Vitamin C
Vitamin E
Lutein – macular carotinoid
Zeaxanthin – foveal carotenoid
Bioflavenoids
–
Ginko biloba – for AMD and glaucoma (blood flow) and memory
Treatment Modalities
Dietary Supplements
– TheraLife Eye & TheraLife Enhancer (TheraLife)
Beta
carotene, bilberry, chrysanthemum, copper, fructus lycii,
Vitamin E & C, riboflavin (B2), selenium, semen cassiae, zinc
–
Hydrate Essential (Cynacon/Ocusoft)
Essential
fatty acids - Flaxseed oil and bilberry extract
encapsulated in hydroxylated lecithin
–
HydroEye (Science Based Health)
Blend
–
of omega fatty acids and nutrients
TheraTears Nutrition (Advanced Vision Research)
EPA
enriched flaxseed oil & omega-3s
Nutritionals and OTC Vitamins
Ocuvite Lutein (B&L)
Ocuvite extra (B&L)
Ocuvite PreserVision (B&L)
–
–
AREDS NIH Study
2 tabs bid
ICAPS Lutein & Zeaxanthin Formula (Alcon)
ICAPS AREDS formula
ICAPS MV
I-Sense OcuShield (Akorn)
Maximize
EyePromise (ZeaVision)
Nutritionals
First degree relatives of ARM pts 2-4 times greater risk
of ARM compared to controls
Twin studies show high levels of concordance of the
disease among monozygotic sibs
Vitamin E may cause bleeding
Vitamin D may be of benefit
Diets high in omega-3 FAs are of benefit
Control of weight, HTN & cholesterol is important
Diet of green leafy vegetables increase lutein,
zeaxanthin which increase optical density of macular
pigment providing protective role
Measurement of Macular Pigment
Objective Techniques
–
–
–
–
–
Modified Fundus Cameras
Fundus Reflectence
Raman Spectroscopy
Autofluorescence Spectroscopy
Modified SLO
Subjective Techniques
–
–
HFP (Heterochromatic Flicker Photometry) (pschyophysical)
(Ability to detect a blue flickering light)
Is MPOD Related to AMD?
Three donor eye studies published, all show 30-50%
less pigment in AMD eyes vs controls
Moran Eye Center (Bernstein) Raman method
Manchester UK group HFP method found AMD patient
eyes had 50% lower MPOD
Germans found 50% lower MPOD in dry AMD patient
eyes
Dutch group did cross sectional prospective study using
reflectance and found no difference on MPOD in early
AMD
The AREDS I & II Formulations
AREDS (Age-Related Eye Disease Study)
Vitamin C: 500 mg*
Vitamin E: 400 IU*
Beta-carotene: 15 mg (May be listed on the label as “25,000 IU
vitamin A as beta-carotene) (eliminate!)
Zinc oxide: 80 mg (40 mg)
Copper: 2 mg (needed to prevent copper deficiency caused by
high dosage of zinc)
Lutein & Zeaxanthin 10 mg & 2 mg
Omega-3 fatty acids 1 gram
Nutritionals
EyePromise (ZeaVision)
–
Zeaxanthin 6mg
in
–
–
–
–
–
–
–
–
the same 1:1 ratio as found in healthy macula
Lutein 6mg
Beta carotene – none
Vitamin C – 120mg
Vitamin E – 60 IU
Zinc – 15mg
Copper – none
Fish oil (omega-3) – 250mg
Alpha Lipoic acid – 10mg
Visual Field 9208x
Bilateral
Requires Interpretation
–
–
separate report form
narrative in body of medical record, on date of service
Fee $44.77- (-81) / $46.18
Fee $58.29- (-82) / $59.09
Fee $66.96- (-83) / $68.17
JAM
Why Is Early Diagnosis Important?
Earlier Diagnosis
Means Better
Final Visual Acuity
Lesion
size was a more
significant factor affecting
treatment benefit than either:
1. Lesion composition
2. Baseline visual acuity
TAP
and VIP Report 1, AJO, Sept., 2003
Average CNV Presentation
Average size:
–
Location:
–
–
80%
20%
Subfoveal
Extrafoveal
Initial Vision:
–
–
–
Olsen, TW Ophthalmology Feb. 2004
3300μ
20%
40%
40%
> 20/40
20/50 – 20/200
< 20/200
Inherent Faults of the Amsler Grid
Completion
–
Fixation
–
The Amsler Grid does not overcome
cortical completion
The Amsler Grid does not force
fixation
Crowding
–
Inhibition by neighboring peripheral
lines reduces detection
Foresee PHP™ Technology
Vernier Acuity
2 sec arc
The human ability to perceive
minute differences in the relative
spatial localization of two objects in
space
The brain is exceptionally sensitized
to the detection of small shifts in the
co-linear arrangement of
photoreceptors.
Hyperacuity
Snellen 20/15 Resolution
– 1minute of arc
– 0.017 degrees
Vernier Resolution
– Two seconds of arc
– 0.03 minutes of arc
– 0.00051 degrees
– The width of a pencil
viewed at 300 m !
The Future of AMD Monitoring
Foresee PHP™
Easy operation
Comfortable for patient
Noninvasive Rapid threshold test ~
5 min/eye
Automated results analysis
Generates visual field map of
disturbance patterns consistent with
the progression of AMD
Thank you
McGreal Educational Institute
Missouri Eye Associates
Excellence in Optometric Education